Skip to content

The Effect of Perioperative Nefopam on Postoperative Pain After Mastectomy: A Randomized Controlled Trial

The Effect of Perioperative Nefopam on Postoperative Pain After Mastectomy: A Randomized Controlled Trial

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
TCTR
Registry ID
TCTR20200806006
Enrollment
66
Registered
2020-08-06
Start date
2020-08-07
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast cancer Postmastectomy pain Breast cancer Mastectomy Nefopam Postmastectomy pain

Interventions

Participants undergoing mastectomy will receive an intravenous nefopam 20 mg added to 0.9% NaCl solution 100 mL preincision&#44
intraoperatively. After surgery&#44
participants will receive an intravenous nefopam 60 mg added to 0.9%NaCl solution 250 mL drip in 24 hour.,Participants undergoing mastectomy will receive an intravenous 0.9%NaCl solution 100 mL preinc
participants will receive an intravenous 0.9%NaCl solution 250 mL drip in 24 hour.
Experimental Drug,Placebo Comparator Drug

Sponsors

Ratchadapisek Sompoch Endowment Fund, Chulalongkorn University
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
20 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Diagnosed with breast cancer 2. Undergoing unilateral simple mastectomy, modified radical mastectomy, radical mastectomy, skin sparing mastectomy, nipple sparing mastectomy with or without axillary lymphnode dissection 3. ASA physical status I-III

Exclusion criteria

Exclusion criteria: 1. Patient refusal 2. Unable to properly use intravenous PCA machine 3. Preexisting chronic pain 4. Currently take analgesic medications within 14 days 5. Currently take monoamine oxidase inhibitor within 14 days 6. Pregnant or lactation 7. Previous surgery (excision or mastectomy) due to breast cancer 8. Medical history of seizure, acute angle-closure glaucoma, myocardial infarction, chronic obstructive pulmonary disease 9. Renal impairment (eGFR lower than 30 mL/min/1.73sq.m.) 10. Acute liver failure or severe liver impairment 11. Contraindicated to any medication using in study protocol

Design outcomes

Primary

MeasureTime frame
Total morphine consumption at 24 hours after surgery collected data from PCA machine in milligram of morphine

Secondary

MeasureTime frame
Total morphine consumption At post anesthesia care unit, at 6 and 48 hours after surgery collected data from PCA machine in milligram of morphine,Severity of pain At post anesthesia care unit, at 6, 24, and 48 hours after surgery Patient reported as verbal numerical rating scale 0-10,Incidence of chronic post operative pain At 3 months after surgery Patient reported during telephone follow up,Incidence of neuropathic pain At 48 hours and 3 months after surgery Patient reported outcome using Thai DN4 questionaire,Adverse events within 48 hours after surgery Patient reported or observed by health care personnels

Countries

Thailand

Contacts

Public ContactSuppanich Mahachairithiporn

King Chulalongkorn Memorial Hospital

smart08880@hotmail.com0847584875

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026